Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs Alemtuzumab vs Combination as Consolidation in CLL
NCT00771602Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2008
- Primary completion
- Dec 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab and alemtuzumab in chronic lymphocytic leukemia (CLL) (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Number of Patients With Molecular Remissions at 52 weeks. Started Aug 2008; status: terminated.
02
Drugs
rituximabalemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00771602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00771602.